Top-Rated Terbinafine Brands for Impressive Results

Terbinafine is a widely used antifungal medication, known for its efficacy in treating a variety of fungal infections. With numerous brands available in the market, selecting the right one can be daunting. Each brand strives to offer a unique formulation and pricing, appealing to different consumer needs. To help you navigate this choice, we have compiled a list of the best brands for terbinafine, highlighting their distinct features and reliability, inviting you to explore the details below.

Illustration of terbinafine

Best brands of terbinafine in 2025

Lamisil

Lamisil, a brand of terbinafine hydrochloride, is a leading antifungal medication produced by Novartis, known for its efficacy in treating fungal infections such as onychomycosis of the toenail and fingernail. Terbinafine, the active ingredient, inhibits fungal cell wall synthesis by targeting squalene epoxidase, and it is highly lipophilic, accumulating in skin, nails, and fatty tissues. The oral form of Lamisil is administered at 250 mg daily for 6 weeks for fingernail onychomycosis and 12 weeks for toenail onychomycosis. The market for terbinafine is projected to grow significantly, with a forecasted market size of US$ 912.6 million by 2030 and a CAGR of 6.4% from 2024 to 2030. Lamisil tablets are over 99% bound to plasma proteins, ensuring effective and sustained action against fungal infections. For more detailed information, visit the Lamisil drug information page.

Terbinex

Terbinafine, marketed under brands like LamISIL and Terbinex, is a highly effective antifungal medication used to treat a variety of fungal infections, including those affecting the scalp, body, groin, feet, fingernails, and toenails. The global market for Terbinafine Hydrochloride is projected to grow significantly, with a forecasted market size of US$ 912.6 million by 2030 and a CAGR of 6.4% from 2024 to 2030. Terbinafine works by inhibiting the enzyme squalene monooxygenase, crucial for ergosterol synthesis, leading to the accumulation of squalene and weakening the fungal cell wall. The medication is well-absorbed orally, with over 70% absorption, though its bioavailability is around 40% due to first-pass metabolism. Major pharmaceutical companies like Novartis and GSK are key players in the Terbinafine market. For more detailed information, you can visit the Mayo Clinic's page on Terbinafine.

Kerasal

Kerasal, a brand under Moberg Pharma, has established itself as a leading producer of terbinafine-based products, particularly with Kerasal Nail(tm), which achieved a market-leading position in the U.S. with a 20% market share by the end of 2013. This product is available at over 30,000 retail outlets, including major chains like Walmart, CVS, and Walgreens. Kerasal Nail(tm) drove an 86% growth rate in sales for the brand in 2013, and it is distributed widely across the U.S. and other markets such as Canada, Spain, and Turkey. The brand's strong performance is attributed to effective consumer marketing and a robust sales force. Kerasal Nail(tm) has also shown significant growth potential, contributing to the company's overall revenue and market expansion. For further details, refer to the company's 2013 report.

Sandoz Terbinafine

Sandoz Terbinafine is a highly regarded brand for terbinafine, a potent antifungal agent of the allylamine type, used to treat various fungal infections such as those of the fingernails, toenails, groin, body, and feet. It is available in 250mg tablets, with a standard dose of one tablet per day, adjustable for patients with kidney problems. The medication is not addictive and is prescribed only by a doctor. Sandoz Terbinafine is known for its effectiveness, with the global terbinafine market, which includes Sandoz, forecasted to grow at a CAGR of 6.4% from 2024 to 2030. The market size for terbinafine is expected to reach US$ 912.6 million by 2030. For more details, please visit the Sandoz Terbinafine page.

Actavis Terbinafine

Actavis, now part of Teva Pharmaceuticals, is a prominent producer of terbinafine, a highly effective antifungal medication. Terbinafine, marketed under various brand names including Lamisil, is used to treat fungal infections of the fingernails and toenails, as well as other skin infections. The global terbinafine market, which includes Actavis's products, is forecast to grow at a CAGR of 6.4% from 2024 to 2030, reaching a market size of US$ 912.6 million by 2030. Actavis's terbinafine formulations are available in both oral and topical forms, ensuring comprehensive treatment options for patients. The company's commitment to quality and efficacy has made its terbinafine products a trusted choice among healthcare professionals.

Apotex Terbinafine

Apotex is a prominent manufacturer of Terbinafine, a highly effective antifungal medication, particularly noted for its role in treating dermatophyte infections. As of 2023, the global Terbinafine Hydrochloride market, which includes Apotex's offerings, was valued at US$ 614 million and is projected to grow to US$ 912.6 million by 2030, with a CAGR of 6.4% during the forecast period. Apotex's contribution to this market is significant, given its extensive distribution and market share. The drug's mechanism involves inhibiting the enzyme squalene monooxygenase, crucial for fungal cell wall synthesis. Apotex's Terbinafine is known for its high bioavailability and effectiveness in treating fungal infections.

Glenmark Terbinafine

Glenmark Pharmaceuticals is a prominent player in the terbinafine hydrochloride market, known for its high-quality formulations. The global terbinafine hydrochloride drug market, which includes Glenmark's products, is forecast to grow at a CAGR of 6.4% from 2024 to 2030, reaching a market size of US$ 912.6 million by 2030. Glenmark's terbinafine offerings are available in both topical and oral forms, catering to various fungal infections such as fingernail and toenail infections. The company's strong presence in the market is attributed to its robust product portfolio and strategic initiatives. As a key competitor, Glenmark continues to expand its business globally, contributing significantly to the market's growth.

Teva Terbinafine

Teva Terbinafine is a prominent brand in the terbinafine market, known for its high efficacy in treating dermatophyte infections of toenails and fingernails. As one of the key players, Teva Pharmaceuticals contributes significantly to the global terbinafine market, which was estimated to be worth US$ 614 million in 2023 and is forecast to reach US$ 912.6 million by 2030 with a CAGR of 6.4%. Teva's terbinafine products are available in various forms, including oral tablets and topical creams, ensuring comprehensive treatment options for patients. The brand's commitment to quality and innovation has made it a trusted name among healthcare professionals and patients alike. With a strong presence in multiple global regions, Teva continues to expand its market share in the terbinafine sector.

Mylan Terbinafine

Mylan Terbinafine, produced by Mylan Pharmaceuticals ULC, is a highly effective antifungal medication, particularly for treating fungal infections of the skin and nails caused by dermatophytes. It is available in 250 mg tablets as terbinafine hydrochloride and is indicated for conditions such as tinea corporis, tinea cruris, and tinea pedis. The product was revised and updated as recently as July 29, 2016, ensuring it meets current medical standards. Mylan Terbinafine is known for its high lipophilicity, allowing it to accumulate in skin, nails, and fatty tissues, enhancing its efficacy. With its strong market presence, Mylan Terbinafine remains a trusted choice among healthcare professionals. For more detailed information, refer to the product monograph.

Aurobindo Pharma Terbinafine

Aurobindo Pharma is a leading producer of terbinafine, a key antifungal medication, with a significant presence in the global market. The company manufactures terbinafine in various forms, including tablets and topical formulations, catering to fungal infections such as those of the fingernails, toenails, and athlete's foot. In 2023, the tablets segment of the terbinafine market, where Aurobindo Pharma is a major player, accounted for a noticeable share of the global market and is projected to experience significant growth. Aurobindo's commitment to quality and its extensive manufacturing capabilities, with over 99% of its APIs produced in-house, contribute to its reputation as a reliable supplier of terbinafine. The company's strategies to expand access to its generic medicines, including terbinafine, have helped reach a broader patient base globally.